Recursion Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Recursion Pharmaceuticals, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). AI-enabled drug discovery platform with differentiated pipeline and strategic partnerships, but success dependent on clinical trial outcomes and achieving financial sustainability. Recursion demonstrates strong technology differentiation and institutional backing, with recent ARK Investment purchases and positive clinical momentum (TUPELO trial results). However, the company faces significant financial headwinds with.
What is Recursion Pharmaceuticals, Inc.'s industry? Recursion Pharmaceuticals, Inc. (recursion.com) operates in Biotechnology / AI-Driven Drug Discovery (TechBio). AskCyborg classifies Recursion Pharmaceuticals, Inc. under Biotechnology / AI-Driven Drug Discovery (TechBio) in its company registry.
Recursion Pharmaceuticals is a clinical-stage TechBio company that uses AI-driven technology to decode biology and accelerate drug discovery. The company develops a proprietary platform called the Recursion OS—an AI-n...
Cyborg Score thesis
AI-enabled drug discovery platform with differentiated pipeline and strategic partnerships, but success dependent on clinical...
Read the full analyst-debate transcript →Get the Latest Recursion Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeRecursion Pharmaceuticals, Inc. Overview
Pro stress-test →Recursion Pharmaceuticals is a clinical-stage TechBio company that uses AI-driven technology to decode biology and accelerate drug discovery. The company develops a proprietary platform called the Recursion OS—an AI-native, end-to-end drug discovery and development system integrating biology, chemistry, and clinical development.
Strategic Profile
Pro stress-test →Recursion differentiates itself through its integration of wet labs, bioinformatics, and NVIDIA-backed supercomputing (BioHive-2) to generate millions of multi-omic data points weekly and train machine learning models at scale. The company has established strategic partnerships with major pharma (Roche, Genentech, Takeda, Bayer) and is advancing a pipeline across oncology, rare disease, and neuroscience with multiple programs in clinical trials.
Competitive Landscape
Pro stress-test →Recursion competes in the emerging AI-native drug discovery space against companies like Exscientia, Tempus AI, and Atomwise, while also competing with traditional biotech on pipeline basis. Its differentiation lies in integrated wet-dry lab infrastructure and proprietary supercomputing, but success requires clinical validation of its AI-designed programs, which remain largely early-stage.
Industry Context
Recursion Pharmaceuticals, Inc. operates in Biotechnology / AI-Driven Drug Discovery (TechBio).
Key facts
Founded: 2013 · Headquarters: Salt Lake City, United States · Revenue: $58M · Market cap: $1.92B